地奥司明/橙皮苷(Diosmin/Hesperidin) - 在研适应症：痔疮_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Venarus、Venoprotep

靶点-

作用机制-

治疗领域

心血管疾病消化系统疾病

在研适应症

痔疮

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C28H34O15

InChIKeyQUQPHWDTPGMPEX-QJBIFVCTSA-N

CAS号520-26-3

查看全部结构式(2)

关联

8

项与地奥司明/橙皮苷相关的临床试验

NCT06367166 / Active, not recruitingN/AIIT

Study of the Effects of Bioflavonoids on Venous Wall Remodeling in Patients With Varicose Veins of the Lower Extremities

The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).

开始日期2023-04-01

申办/合作机构

Ryazan State Medical University

NCT05243706 / Unknown status临床3期IIT

Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy

All vinca alkaloids causes neuropathy. The incidence of peripheral neuropathy is 30 %-40 % in patients treated with vincristine. The incidence of long term neurological adverse events from vinblastine ranged from 50% to 97%. In this study, the investigators will study the effect of using either loratadine or diosmin 450mg/ hesperidin 50 mg combination on neuropathy caused by Vinca alkaloids therapy. This study is a prospective, controlled, randomized, interventional and open-label clinical trial.

开始日期2022-03-01

申办/合作机构

Ain Shams University

NCT05158192 / Completed临床1期

Bioavailability of a Formulation of Diosmin/Hesperidin (90/10) 500 mg Tablets With Regards to the Marketed Reference Product

This Pilot study investigated the bioavailability in adult human subjects of 1 tablet formulations containing Diosmin/Hesperidin (90/10) 500 mg. The Pilot study was performed at a single site with 12 subjects. Participants took 1 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There was a washout of 7 days between each study period.

开始日期2021-11-04

申办/合作机构

Laboratorios Andrómaco SA

100 项与地奥司明/橙皮苷相关的临床结果

登录后查看更多信息

100 项与地奥司明/橙皮苷相关的转化医学

登录后查看更多信息

100 项与地奥司明/橙皮苷相关的专利（医药）

登录后查看更多信息

8

项与地奥司明/橙皮苷相关的文献（医药）

2017-01-01·International Angiology3区 · 医学

Sulodexide and phlebotonics in the treatment of venous ulcer

3区 · 医学

Article

作者: González Ochoa, Alejandro

BACKGROUNDIn the treatment of venous leg ulcers, vasoactive drugs such as diosmin-hesperidin micronized purified flavonoids (DH) and, more recently, sulodexide (SDX), have been used besides compression therapy and local measures. The purpose of this study was to investigate whether the combined administration of both SDX and DH is better than DH alone in the treatment of venous ulcers.METHODSIn an open-label, observational, non-parallel trial, 70 patients (90 venous ulcers) were treated with multi-layer bandaging, local measures and DH, 37 patients (50 ulcers) also received SDX, 33 patients (40 ulcers) without SDX were the control group. The evolution of leg ulcers and lipodermatosclerosis was evaluated by computerized imaging measurement.RESULTSThe initial clinical characteristics of both groups were similar. Ulcer size showed a faster reduction in the group receiving SDX (P<0.01). With SDX, all of the ulcers were healed by week 12, in the control group, all ulcers were healed at week 21 (P<0.01 between groups). Lipodermatosclerosis improved in both groups, but it decreased faster in the SDX group. No adverse effects attributed to the medications were seen in either group.CONCLUSIONSThe combined administration of SDX and DH was effective in accelerating ulcer healing, controlling pain and improving lipodermatosclerosis.

2015-12-01·Revista da Escola de Enfermagem da USP4区 · 医学

Prevenção da nefrotoxicidade da anfotericina B por meio do uso de fitomedicamentos

4区 · 医学

ArticleOA

作者: Vattimo, Maria de Fatima Fernandes ; Cordeiro, Priscilla ; Fernandes, Sheila Marques ; Martins, Daniel Malisani ; Schlottfeldt, Fábio dos Santos ; Watanabe, Mirian ; Fonseca, Cassiane Dezoti da

2015-09-01·Vnitrni lekarstvi

[Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].

Review

作者: Hnátek, Lukáš

Chronic venous disorder (CVD) is a common illness with high incidence existing especially in Europe and North America. The main goal of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin is to eliminate the symptoms of CVD (venous pain, fatigue, etc). But MPFF of diosmin and hesperidin has good effectiveness for treatment of venous oedema and venous ulcer too. There are many papers that prove its effectiveness in the experiment and in the microcirculation too. The other indications for MPFF of diosmin hesperidin is hemorrhoidal disease and the accessory treatment of lymphedema. It is proved that this substance could be used as an effective supplementary treatment of symptoms after venous intervention. Only MPFF diosmin and hesperidin received the best recommendation - 1B in the last guidelines for VAD therapy.

100 项与地奥司明/橙皮苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	C05CA53	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
痔疮	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISN WCN2024	N/A	肾脏疾病	-	Polyethylene glycol	簾範鏇糧顧醖廠觸壓糧(糧淵廠繭範鑰衊窪網齋) = 網選夢壓選壓艱製膚製網膚網蓋積網壓繭艱衊 (蓋鏇網鹽鹽糧繭製憲糧 )	-	2024-04-01
				Diosmin-hesperidin	簾範鏇糧顧醖廠觸壓糧(糧淵廠繭範鑰衊窪網齋) = 範蓋鹹積鹽糧範餘網簾網膚網蓋積網壓繭艱衊 (蓋鏇網鹽鹽糧繭製憲糧 )